Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Effects of rituximab on lymphocytes in multiple sclerosis and neuromyelitis optica.
BTG Commences Phase IIa Study of Multiple Sclerosis
Neuropathology of white matter disease in Leber's hereditary optic neuropathy.
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
GeNeuro and Servier sign partnership to develop first medicine addressing a causal factor of multiple sclerosis
CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
Genzyme’s Lemtrada™ approved in Australia for treatment of multiple sclerosis
Axonal conduction and injury in multiple sclerosis: the role of sodium channels.
High-dose cyclophosphamide without stem cell rescue in 207 patients with aplastic anemia and other autoimmune diseases.
Durable pharmacological responses from the peptide drug ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage.
Interferon β-1a reduces increased interleukin-16 levels in multiple sclerosis patients.
Therapeutic induction of regulatory, cytotoxic CD8+ T cells in multiple sclerosis.
Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain.
Vitamin D-dependent rickets, HLA-DRB1, and the risk of multiple sclerosis.
Teva to present positive data for glatiramer acetate 40 mg/1 ml given three times weekly for relapsing-remitting MS
Calcitriol Modulates the CD46 Pathway in T Cells.
Active Biotech's partner Teva initiates a further clinical trial in multiple sclerosis
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
Epigenetic mechanisms in multiple sclerosis and the major histocompatibility complex (MHC).
Multiple associations between a broad spectrum of autoimmune diseases, chronic inflammatory diseases and cancer.
Stress Management and Multiple Sclerosis: A Randomized Controlled Trial.
Genetics of multiple sclerosis: swimming in an ocean of data.
Biomarkers for Brain Disorders: Challenges and Opportunities
Generic interferon-beta
Pages
« first
‹ previous
…
128
129
130
131
132
133
134
135
136
…
next ›
last »